GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (LSE:AGL) » Definitions » Institutional Ownership

ANGLE (LSE:AGL) Institutional Ownership : 7.15% (As of Jun. 07, 2024)


View and export this data going back to 2004. Start your Free Trial

What is ANGLE Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ANGLE's institutional ownership is 7.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ANGLE's Insider Ownership is 3.35%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ANGLE's Float Percentage Of Total Shares Outstanding is 0.00%.


ANGLE Institutional Ownership Historical Data

The historical data trend for ANGLE's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANGLE Institutional Ownership Chart

ANGLE Historical Data

The historical data trend for ANGLE can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 10.21 10.21 9.12 7.59 7.58 7.29 7.16 7.15 7.15 7.15

ANGLE Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


ANGLE (LSE:AGL) Business Description

Traded in Other Exchanges
Address
10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
ANGLE PLC is active in the healthcare sector in the United Kingdom. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which majority of its revenue is generated from Europe.